Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADIUVO-2: Adjuvant Mitotane vs. Mitotane + Cisplatin/Etoposide in High-Risk Adrenocortical Carcinoma
NCT03583710Phase 3Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2018
- Primary completion
- Jan 2029
- Modality
- Nanoparticles, Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of Cisplatin micelle injection (HA132), etoposide in adrenocortical carcinoma (ACC), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2018; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)etoposide
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT03583710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583710.